BR0314552A - Métodos para prognosticar elevações de colesterol durante terapia imunossupressora - Google Patents

Métodos para prognosticar elevações de colesterol durante terapia imunossupressora

Info

Publication number
BR0314552A
BR0314552A BR0314552-2A BR0314552A BR0314552A BR 0314552 A BR0314552 A BR 0314552A BR 0314552 A BR0314552 A BR 0314552A BR 0314552 A BR0314552 A BR 0314552A
Authority
BR
Brazil
Prior art keywords
methods
predict
immunosuppressive therapy
elevations during
cholesterol
Prior art date
Application number
BR0314552-2A
Other languages
English (en)
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Rosarelis Torres
Curt Douglas Wolfgang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314552(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0314552A publication Critical patent/BR0314552A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODOS PARA PROGNOSTICAR ELEVAçõES DE COLESTEROL DURANTE TERAPIA IMUNOSSUPRESSORA". Esta invenção proporciona métodos para prognosticar o grau de elevação de níveis de colesterol sérico em pacientes tratados com medicação imunossupressora. Esta invenção também proporciona estratégias de tratamento com base nessas predições e kits para realizar esses métodos.
BR0314552-2A 2002-09-30 2003-09-29 Métodos para prognosticar elevações de colesterol durante terapia imunossupressora BR0314552A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41512302P 2002-09-30 2002-09-30
PCT/EP2003/010798 WO2004029618A2 (en) 2002-09-30 2003-09-29 Methods to predict cholesterol elevations during immunosuppressant therapy

Publications (1)

Publication Number Publication Date
BR0314552A true BR0314552A (pt) 2005-08-09

Family

ID=32043422

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314552-2A BR0314552A (pt) 2002-09-30 2003-09-29 Métodos para prognosticar elevações de colesterol durante terapia imunossupressora

Country Status (14)

Country Link
US (2) US7732134B2 (pt)
EP (1) EP1549770B1 (pt)
JP (1) JP4575775B2 (pt)
CN (1) CN100453650C (pt)
AT (1) ATE389034T1 (pt)
AU (1) AU2003287955B2 (pt)
BR (1) BR0314552A (pt)
CA (1) CA2500979A1 (pt)
DE (1) DE60319719T2 (pt)
ES (1) ES2302959T3 (pt)
HK (1) HK1084445A1 (pt)
IL (1) IL167639A (pt)
PT (1) PT1549770E (pt)
WO (1) WO2004029618A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015083A (es) * 2005-05-31 2008-01-17 Novartis Ag Combinacion de inhibidores de hmg-coa-reductasa e inhibidores de mtor.
GB2488289A (en) 2009-11-06 2012-08-22 Univ Leland Stanford Junior Non-invasive diagnosis of graft rejection in organ transplant patients
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6524795B1 (en) 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
CA2467717A1 (en) * 2001-11-19 2003-05-30 Interleukin Genetics, Inc. Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases

Also Published As

Publication number Publication date
AU2003287955A1 (en) 2004-04-19
CN100453650C (zh) 2009-01-21
JP2006500930A (ja) 2006-01-12
DE60319719D1 (de) 2008-04-24
HK1084445A1 (en) 2006-07-28
PT1549770E (pt) 2008-06-24
AU2003287955B2 (en) 2007-06-21
CN1685062A (zh) 2005-10-19
US20100184798A1 (en) 2010-07-22
US7732134B2 (en) 2010-06-08
US20060246439A1 (en) 2006-11-02
AU2003287955B9 (en) 2004-04-19
WO2004029618A3 (en) 2004-06-17
EP1549770B1 (en) 2008-03-12
DE60319719T2 (de) 2009-03-12
IL167639A (en) 2011-10-31
ATE389034T1 (de) 2008-03-15
ES2302959T3 (es) 2008-08-01
WO2004029618A2 (en) 2004-04-08
EP1549770A2 (en) 2005-07-06
CA2500979A1 (en) 2004-04-08
JP4575775B2 (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
HK1091112A1 (en) Compounds and methods for increasing neurogenesis
RS20050885A (sr) Lečenje sa anti-vegf antitelima
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
CY1105892T1 (el) Θepαπεια του ξανθωματος με παραγωγα αζετιδινονης ως αναστολεις απορροφησης στepολης
DE60325628D1 (de) Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
MXPA04006572A (es) Terapia de combinacion antivirica.
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
BR0214821A (pt) Métodos de tratamento da psicose e esquizofrenia com base nos polimorfismos no gene cntf
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
HK1084445A1 (en) Methods to predict cholesterol elevations during immunosuppressant therapy
NO20053903D0 (no) Nukleotidlipidesterderivater.
DK1392355T3 (da) Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
EA200601871A1 (ru) Способы лечения аутоиммунных и воспалительных заболеваний
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
PL1604211T3 (pl) Identyfikowanie związków terapeutycznych
TR200200278T2 (tr) Kalsilitik bileşimler
UA86749C2 (en) THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
BR0113646A (pt) Tratamento de distúrbios inflamatórios

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2273 DE 29/07/2014.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.